Search Results - "Attinger-Toller, Isabella" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

by Silacci, Michela, Lembke, Wibke, Woods, Richard, Attinger-Toller, Isabella, Baenziger-Tobler, Nadja, Batey, Sarah, Santimaria, Roger, von der Bey, Ulrike, Koenig-Friedrich, Susann, Zha, Wenjuan, Schlereth, Bernd, Locher, Mathias, Bertschinger, Julian, Grabulovski, Dragan
Published in mAbs (01.01.2016)

Get full text

Journal Article

아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법

아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법

by GRABULOVSKI DRAGAN, BERTRAND ROMAIN, ATTINGER TOLLER ISABELLA, SPYCHER PHILIPP
Year of Publication 18.05.2023

Get full text

Patent

Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity

Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity

by Wuellner, Ulrich, Klupsch, Kristina, Buller, Fabian, Attinger-Toller, Isabella, Santimaria, Roger, Zbinden, Irene, Henne, Patricia, Grabulovski, Dragan, Bertschinger, Julian, Brack, Simon
Published in Antibodies (Basel) (08.12.2015)

Get full text

Journal Article

항체-링커 접합체를 생성하기 위한 수단 및 방법

항체-링커 접합체를 생성하기 위한 수단 및 방법

by PROBST PHILIPP, GRABULOVSKI DRAGAN, BERTRAND ROMAIN, STARK RAMONA, ATTINGER TOLLER ISABELLA, SPYCHER PHILIPP
Year of Publication 29.06.2023

Get full text

Patent

Abstract 1842: CD79b targeting ADC with superior pharmacokinetic profile and anti-tumor activity

by Spycher, Philipp René, Probst, Philipp, Bertrand, Romain, Stark, Ramona, Santimaria, Roger, Grabulovski, Dragan, Attinger-Toller, Isabella
Published in Cancer research (Chicago, Ill.) (01.07.2021)

Get full text

Journal Article

FYNOMER ANTIBODY-FYNOMER CONJUGATES

FYNOMER ANTIBODY-FYNOMER CONJUGATES

by NEWMAN ROLAND, GRANGER STEVE, ZHA WENJUAN, GRABULOVSKI DRAGAN, WOODS RICHARD, SILACCI MICHELA, LYMAN MICHAEL, ATTINGER TOLLER ISABELLA
Year of Publication 16.11.2016

Get full text

Patent

A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC

A CD79b Targeting ADC with Superior Anti-Tumor Activity and Safety Resulting in Significantly Improved Therapeutic Index (TI): Safe and Efficacious CD79b ADC

by Schlereth, Bernd, Attinger-toller, Isabella, Probst, Philipp, Bertrand, Romain, Stark, Ramona, Santimaria, Roger, Renard, Emma, Fay, Rachael, Sharman, Jeff P., Grabulovski, Dragan, Spycher, Philipp
Published in Blood (15.11.2022)

Get full text

Journal Article

A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action

A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action

by Brack, Simon, Attinger-Toller, Isabella, Schade, Babette, Mourlane, Frédéric, Klupsch, Kristina, Woods, Richard, Hachemi, Helen, von der Bey, Ulrike, Koenig-Friedrich, Susann, Bertschinger, Julian, Grabulovski, Dragan
Published in Molecular cancer therapeutics (01.08.2014)

Get full text

Journal Article

Abstract LB-106: Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology

Abstract LB-106: Overcoming limitations of current Antibody-Drug Conjugates (ADCs) by a novel linker technology

by Spycher, Philipp Rene, Frei, Julia Carina, Wehrmüller, Jöri Elias, Attinger-toller, Isabella, Grabulovski, Dragan, Hechler, Torsten, Kulke, Michael, Pahl, Andreas, Behe, Martin, Schibli, Roger
Published in Cancer research (Chicago, Ill.) (01.07.2019)

Get full text

Journal Article

Abstract LB221: Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses

Abstract LB221: Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses

by Attinger-Toller, Isabella, Probst, Philipp, Bertrand, Romain, Renard, Emma, Stark, Ramona, Santimaria, Roger, Grabulovski, Dragan, Schlereth, Bernd, Spycher, Philipp Rene
Published in Cancer research (Chicago, Ill.) (14.04.2023)

Get full text

Journal Article

Abstract LB219: Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation

Abstract LB219: Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation

by Attinger-Toller, Isabella, Fay, Rachael, Bertrand, Romain, Probst, Philipp, Stark, Ramona, Santimaria, Roger, Grabulovski, Dragan, Schlereth, Bernd, Spycher, Philipp Rene
Published in Cancer research (Chicago, Ill.) (14.04.2023)

Get full text

Journal Article

Abstract LB124: Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo

Abstract LB124: Targeting NaPi2b with a novel dual TOP1i ADC that shows excellent biophysical properties and high efficacy in vivo

by Attinger-Toller, Isabella, Probst, Philipp, Kallenberger, Lia, Renard, Emma, Bertrand, Romain, Fay, Rachael, Santimaria, Roger, Maurhofer, Patrick, Grabulovski, Dragan, Schlereth, Bernd, Spycher, Philipp Rene
Published in Cancer research (Chicago, Ill.) (05.04.2024)

Get full text

Journal Article

Abstract 2600: Novel dual TOP1i ADC inducing superior tumour growth inhibition at low-drug load vs. trastuzumab deruxtecan

Abstract 2600: Novel dual TOP1i ADC inducing superior tumour growth inhibition at low-drug load vs. trastuzumab deruxtecan

by Spycher, Philipp, Fay, Rachael, Bertrand, Romain, Probst, Philipp, Stark, Ramona, Santimaria, Roger, Maurhofer, Patrick, Kallenberger, Lia, Renard, Emma, Schlereth, Bernd, Grabulovski, Dragan, Attinger-Toller, Isabella
Published in Cancer research (Chicago, Ill.) (22.03.2024)

Get full text

Journal Article

Abstract LB174: Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation

Abstract LB174: Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation

by Attinger-Toller, Isabella, Probst, Philipp, Bertrand, Romain, Stark, Ramona, Santimaria, Roger, Grabulovski, Dragan, Schlereth, Bernd, Spycher, Philipp
Published in Cancer research (Chicago, Ill.) (15.06.2022)

Get full text

Journal Article

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

by Klupsch, Kristina, Baeriswyl, Vanessa, Scholz, Roland, Dannenberg, Joana, Santimaria, Roger, Senn, David, Kage, Elena, Zumsteg, Adrian, Attinger-Toller, Isabella, von der Bey, Ulrike, König-Friedrich, Susann, Dupuy, Fanny, Lembke, Wibke, Albani, Clara, Wendelspiess, Severin, Dinkel, Lucijana, Saro, Dorina, Hepler, Robert W, Laszlo, George S, Gudgeon, Chelsea J, Bertschinger, Julian, Brack, Simon, Walter, Roland B
Published in Leukemia (01.03.2019)

Get full text

Journal Article

Abstract 2910: A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

Abstract 2910: A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

by Attinger-Toller, Isabella, Probst, Philipp, Bertrand, Romain, Stark, Ramona, Santimaria, Roger, Renard, Emma, Fay, Rachael, Grabulovski, Dragan, Schlereth, Bernd, Spycher, Philipp René
Published in Cancer research (Chicago, Ill.) (15.06.2022)

Get full text

Journal Article

Abstract 1787: COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

Abstract 1787: COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia

by Klupsch, Kristina, Baeriswyl, Vanessa, Scholz, Roland, Dannenberg, Joana, Santimaria, Roger, Senn, David, Kage, Elena, Zumsteg, Adrian, Attinger-Toller, Isabella, Bey, Ulrike von der, König-Friedrich, Susann, Dupuy, Fanny, Lembke, Wibke, Albani, Clara, Wendelspiess, Severin, Dinkel, Lucijana, Gudgeon, Chelsea J., Walter, Roland B., Bertschinger, Julian, Brack, Simon
Published in Cancer research (Chicago, Ill.) (01.07.2018)

Get full text

Journal Article

Abstract 658: A bispecific HER2 targeting FynomAb with superior anti-tumor activity and novel mode of action

Abstract 658: A bispecific HER2 targeting FynomAb with superior anti-tumor activity and novel mode of action

by Schade, Babette, Brack, Simon, Attinger-Toller, Isabella, Klupsch, Kristina, Woods, Richard, Hachemi, Helen, Bey, Ulrike von der, Koönig-Friedrich, Susann, Bertschinger, Julian, Grabulovski, Dragan
Published in Cancer research (Chicago, Ill.) (01.10.2014)

Get full text

Journal Article

Abstract 656: A bispecific HER2/CD3 targeting FynomAb with excellent tumor killing and favorable pharmacokinetic properties

Abstract 656: A bispecific HER2/CD3 targeting FynomAb with excellent tumor killing and favorable pharmacokinetic properties

by Wuellner, Ulrich, Buller, Fabian, Klupsch, Kristina, Brack, Simon, Zbinden, Irene, Santimaria, Roger, Attinger-Toller, Isabella, König-Friedrich, Susann, Bertschinger, Julian, Grabulovski, Dragan
Published in Cancer research (Chicago, Ill.) (01.10.2014)

Get full text

Journal Article

Fynomer-antibody fusions targeting HER2 and CD3 for selective killing of HER2 overexpressing tumor cells

Fynomer-antibody fusions targeting HER2 and CD3 for selective killing of HER2 overexpressing tumor cells

by Woods, Richard, Brack, Simon, Klupsch, Kristina, Wuellner, Ulrich, Buller, Fabian, Santimaria, Roger, Attinger-Toller, Isabella, Koenig-Friedrich, Susann, Zbinden, Irene, Bertschinger-Ehrler, Julian, Grabulovski, Dragan
Published in Journal of clinical oncology (20.05.2014)

Get full text

Journal Article